睿知中国医院研究地图
候选清单

正在招募多发性骨髓瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07579234,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Have relapsed or refractory multiple myeloma (RRMM) who have previously failed therapy with regimens containing at least one agent from each of the following three drug classes: proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies; i. Relapsed: Disease progression requiring salvage therapy after achieving a minimal response (MR) or better following prior anti-myeloma therapy; ii. Refractory: Lack of response (failure to achieve MR or better) during the last anti-myeloma therapy, or disease progression within 60 days after the last anti-myeloma therapy;

    入选标准第 3 条

    History of any other malignancy within 3 years prior to first dose, except for malignancies with very low recurrence risk after curative treatment (e.g., squamous cell carcinoma or basal cell carcinoma of the skin, in situ cervical or breast cancer), or those who have undergone curative surgical resection (or other treatment) with no current evidence of disease and unlikely to impact survival during the study period;

    排除标准第 3 条

    Underwent major surgery within 4 weeks prior to first dose, or anticipated to undergo major surgery during the study period;

    排除标准第 22 条

    Previously received pomalidomide or have a contraindication to pomalidomide (e.g., history of arterial or deep vein thrombosis within the past 3 months [except intermuscular vein thrombosis], contraindication to or unwillingness to receive prophylactic antithrombotic therapy as required by protocol), or life-threatening allergic reaction or intolerance to pomalidomide;

    排除标准第 40 条

  3. Have an ECOG performance status of 0-2;

    入选标准第 5 条

  4. Hematology: Absolute neutrophil count (ANC) ≥1.0×10⁹/L, hemoglobin ≥70 g/L, platelets ≥50×10⁹/L;

    入选标准第 11 条

    Liver function: Total bilirubin ≤1.5×ULN, ALT ≤2.5×ULN, AST ≤2.5×ULN;

    入选标准第 12 条

    Renal function: Creatinine clearance ≥30 mL/min;

    入选标准第 13 条

    HBsAg positive and/or HbcAb positive with HBV-DNA positive or above upper limit of normal (ULN); HCV antibody positive with HCV-RNA positive or above ULN;

    排除标准第 17 条

  5. Active autoimmune disease, including HIV infection. Patients with well-controlled type 1 diabetes, euthyroid autoimmune thyroiditis, or skin diseases not requiring systemic therapy (e.g., vitiligo, psoriasis) are permitted;

    排除标准第 18 条

    Active tuberculosis (evidenced by chest imaging or other relevant testing within 3 months prior to screening or during screening; tuberculosis screening will be conducted per center protocol);

    排除标准第 20 条

  6. Pregnant or lactating women; male participants (or their partners) or female participants who plan to become pregnant during the study or within 6 months after the last dose, and who are unwilling to use a medically accepted effective contraceptive method (e.g., intrauterine device or condom) during the study period;

    排除标准第 34 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07579234,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients must meet all of the following inclusion criteria to be eligible for enrollment in this study:
  2. Provide informed consent and voluntarily sign the informed consent form; Be male or female, aged ≥18 years;
  3. Have relapsed or refractory multiple myeloma (RRMM) who have previously failed therapy with regimens containing at least one agent from each of the following three drug classes: proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies; i. Relapsed: Disease progression requiring salvage therapy after achieving a minimal response (MR) or better following prior anti-myeloma therapy; ii. Refractory: Lack of response (failure to achieve MR or better) during the last anti-myeloma therapy, or disease progression within 60 days after the last anti-myeloma therapy;
  4. Before randomization, the investigator must pre-select a standard of care (SOC) treatment regimen based on the patient's disease status;
  5. Have an ECOG performance status of 0-2;
  6. Have at least one measurable disease parameter:
  7. Serum M-protein ≥5 g/L;
  8. Urine M-protein ≥200 mg/24 h;
  9. Serum free light chain (FLC) assay: involved FLC level ≥100 mg/L with an abnormal serum FLC ratio (<0.26 or >1.65);
  10. Have organ function meeting the following requirements (no blood components or hematopoietic growth factors permitted within 7 days prior to first dose):
  11. Hematology: Absolute neutrophil count (ANC) ≥1.0×10⁹/L, hemoglobin ≥70 g/L, platelets ≥50×10⁹/L;
  12. Liver function: Total bilirubin ≤1.5×ULN, ALT ≤2.5×ULN, AST ≤2.5×ULN;
  13. Renal function: Creatinine clearance ≥30 mL/min;
  14. All prior treatment-related toxicities (as defined by NCI CTCAE v6.0) must be ≤Grade 1 at screening, except for alopecia, non-clinically significant and asymptomatic Grade 2 laboratory abnormalities, and those parameters specifically permitted in the inclusion criteria;
  15. Have an expected survival of ≥3 months.

排除标准:Exclusion Criteria:

  1. Central nervous system involvement or clinical symptoms of meningeal involvement by multiple myeloma;
  2. Concomitant light chain amyloidosis, plasma cell leukemia, Waldenström macroglobulinemia, or POEMS syndrome;
  3. History of any other malignancy within 3 years prior to first dose, except for malignancies with very low recurrence risk after curative treatment (e.g., squamous cell carcinoma or basal cell carcinoma of the skin, in situ cervical or breast cancer), or those who have undergone curative surgical resection (or other treatment) with no current evidence of disease and unlikely to impact survival during the study period;
  4. Dysphagia or active gastrointestinal dysfunction that may impair drug absorption;
  5. Evidence of cardiovascular risk, including any of the following:
  6. QTc interval: ≥450 ms in males, ≥470 ms in females (QT interval must be corrected for heart rate using Friderici's formula);
  7. Left ventricular ejection fraction (LVEF) <50%;
  8. Electrocardiographic abnormalities deemed by the investigator to pose unacceptable risk, including clinically significant untreated or uncontrolled arrhythmias, second-degree (Mobitz II) or third-degree atrioventricular (AV) block;
  9. History of myocardial infarction, acute coronary syndrome (including unstable angina), coronary angioplasty, stent placement, or bypass surgery within 6 months prior to screening;
  10. Heart failure classified as NYHA Class III or IV;
  11. Uncontrolled severe hypertension (systolic blood pressure ≥170 mmHg or diastolic blood pressure ≥110 mmHg);
  12. Active infection requiring antimicrobial, antiviral, or antifungal therapy (prophylactic therapy excluded):
  13. Oral antimicrobial therapy within 2 weeks prior to first dose;
  14. Intravenous antimicrobial therapy within 4 weeks prior to first dose;
  15. History of viral respiratory infection (e.g., COVID-19, influenza A or B) within 2 weeks prior to first dose;
  16. Serological findings:
  17. HBsAg positive and/or HbcAb positive with HBV-DNA positive or above upper limit of normal (ULN); HCV antibody positive with HCV-RNA positive or above ULN;
  18. Active autoimmune disease, including HIV infection. Patients with well-controlled type 1 diabetes, euthyroid autoimmune thyroiditis, or skin diseases not requiring systemic therapy (e.g., vitiligo, psoriasis) are permitted;
  19. Active syphilis infection;
  20. Active tuberculosis (evidenced by chest imaging or other relevant testing within 3 months prior to screening or during screening; tuberculosis screening will be conducted per center protocol);
  21. Received live or attenuated vaccine within 4 weeks prior to first dose;
  22. Underwent major surgery within 4 weeks prior to first dose, or anticipated to undergo major surgery during the study period;
  23. Received the following anti-myeloma therapies prior to first dose:
  24. Plasmapheresis within 28 days prior to first dose;
  25. Monoclonal antibody therapy within 21 days prior to first dose;
  26. Small molecule targeted therapy, cytotoxic chemotherapy, and/or proteasome inhibitor and/or other anti-tumor traditional Chinese medicine within 14 days or 5 half-lives (whichever is shorter) prior to first dose;
  27. Systemic corticosteroids (prednisone >10 mg/day or equivalent dose) within 7 days prior to first dose;
  28. Autologous stem cell transplantation within 3 months prior to first dose;
  29. CAR-T or CAR-NK cell therapy within 3 months prior to first dose;
  30. Previously received allogeneic stem cell transplantation;
  31. Previously received BCMA-targeted therapy;
  32. Plan to receive other anticancer therapy or investigational drugs during the study period;
  33. Any severe and/or unstable pre-existing medical condition, psychiatric disorder, or other disease (including laboratory abnormalities) that may affect participant safety, informed consent acquisition, or adherence to study procedures;
  34. Pregnant or lactating women; male participants (or their partners) or female participants who plan to become pregnant during the study or within 6 months after the last dose, and who are unwilling to use a medically accepted effective contraceptive method (e.g., intrauterine device or condom) during the study period;
  35. Any patient deemed unsuitable for participation by the investigator..
  36. Inability to receive bortezomib as determined by the investigator;
  37. Contraindication to bortezomib or history of life-threatening allergic reaction or intolerance (defined as drug-related AE leading to discontinuation of treatment);
  38. Grade 1 peripheral neuropathy with pain or Grade ≥2 peripheral neuropathy;
  39. Received a strong CYP3A4 inducer within 5 half-lives prior to first dose;
  40. Previously received pomalidomide or have a contraindication to pomalidomide (e.g., history of arterial or deep vein thrombosis within the past 3 months [except intermuscular vein thrombosis], contraindication to or unwillingness to receive prophylactic antithrombotic therapy as required by protocol), or life-threatening allergic reaction or intolerance to pomalidomide;
  41. Previously received selinexor or have a contraindication to selinexor or life-threatening allergic reaction or intolerance to selinexor.

引自 ClinicalTrials.gov, NCT07579234, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07579234,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07579234